GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SARTF) » Definitions » Net Change in Cash

Sartorius AG (Sartorius AG) Net Change in Cash : $1,031 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sartorius AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sartorius AG's Net Change in Cash for the three months ended in Mar. 2024 was $787 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $1,031 Mil.

Sartorius AG Net Change in Cash Historical Data

The historical data trend for Sartorius AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Net Change in Cash Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.55 181.26 157.06 -187.39 232.61

Sartorius AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.67 10.83 140.56 93.02 786.52

Sartorius AG Net Change in Cash Calculation

Sartorius AG's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=930.862+-3078.844+2361.723+18.866
=233

Sartorius AG's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=49.348+-147.065+883.478+0.761
=787

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,031 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (Sartorius AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SARTF) » Definitions » Net Change in Cash
Comparable Companies
MIL:SFL ISRG XPAR:EL BDX TSE:7741 XSWX:ALC OCSE:COLO B RMD WST XPAR:DIM TSE:4543 XSWX:STMN BAX COO HOLX TSE:7733 XTER:AFX TSE:6869 TFX SZSE:300896
Traded in Other Exchanges
SOAGY:USA SSSGY:USA SUVPF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria
Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Website
https://www.sartorius.com
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.

Sartorius AG (Sartorius AG) Headlines

From GuruFocus

Sartorius to acquire Novasep's chromatography process equipment division

By PRNewswire PRNewswire • 01-06-2021

Sartorius To Join The DAX Blue Chip Index

By PRNewswire PRNewswire • 09-04-2021

Sartorius with first-quarter uptick in sales and earnings

By PRNewswire PRNewswire • 04-21-2021

Sartorius completes acquisition of Novasep's chromatography division

By PRNewswire PRNewswire • 02-08-2022

Sartorius closes acquisition of BIA Separations

By PRNewswire PRNewswire • 11-02-2020

Sartorius acquires cell culture specialist Xell AG

By PRNewswire PRNewswire • 07-29-2021

Sartorius to expand Business Operations in North America

By PRNewswire PRNewswire • 09-27-2021

Sartorius to Open New Application and Service Hub in Shanghai

By PRNewswire PRNewswire • 09-16-2021

Sartorius grows dynamically and profitably - Substantial double-digit increases in sales and earnings

By PRNewswire PRNewswire • 10-20-2021

Resolutions of the Annual General Shareholders' Meeting of Sartorius AG

By PRNewswire PRNewswire • 03-25-2022